The impact of next generation sequencing on the analysis of breast cancer susceptibility: a role for extremely rare genetic variation?

被引:19
作者
Hilbers, F. S. M. [1 ]
Vreeswijk, M. P. G. [1 ,2 ]
van Asperen, C. J. [3 ]
Devilee, P. [1 ,4 ]
机构
[1] Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 ZA Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Toxicogenet, NL-2333 ZA Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Clin Genet, NL-2333 ZA Leiden, Netherlands
[4] Leiden Univ, Med Ctr, Dept Pathol, NL-2333 ZA Leiden, Netherlands
关键词
breast cancer; familial risk; genetics; sequencing technology; HIGH-RISK BREAST; GERMLINE MUTATIONS; FANCONI-ANEMIA; EARLY-ONSET; MISSENSE MUTATIONS; BARD1; MUTATIONS; GASTRIC-CANCER; ATM MUTATIONS; DNA-DAMAGE; BRCA2; GENE;
D O I
10.1111/cge.12256
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Women with a family history of breast cancer have an approximately twofold elevated risk of the disease. Even though an array of genes has been associated with breast cancer risk the past two decades, variants within these genes jointly explain at most 40% of this familial risk. Many explanations for this missing heritability' have been proposed, including the existence of many very rare variants, interactions between genetic and environmental factors and structural genetic variation. In this review, we discuss how next generation sequencing will teach us more about the genetic architecture of breast cancer, with a specific focus on very rare genetic variants. While such variants potentially explain a substantial proportion of familial breast cancer, assessing the breast cancer risks conferred by them remains challenging, even if this risk is relatively high. To assess more moderate risks, epidemiological approaches will require very large patient cohorts to be genotyped for the variant, only achievable through international collaboration. How well we will be able to eventually resolve the missing heritability for breast cancer in a clinically meaningful way crucially depends on the underlying complexity of the genetic architecture.
引用
收藏
页码:407 / 414
页数:8
相关论文
共 89 条
[1]   A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes [J].
Antoniou, AC ;
Pharoah, PDP ;
McMullan, G ;
Day, NE ;
Stratton, MR ;
Peto, J ;
Ponder, BJ ;
Easton, DF .
BRITISH JOURNAL OF CANCER, 2002, 86 (01) :76-83
[2]   Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study [J].
Antoniou, AC ;
Pharoah, PDP ;
McMullan, G ;
Day, NE ;
Ponder, BAJ ;
Easton, D .
GENETIC EPIDEMIOLOGY, 2001, 21 (01) :1-18
[3]  
Baris HN, 2007, ISR MED ASSOC J, V9, P847
[4]   Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene [J].
Bartkova, Jirina ;
Tommiska, Johanna ;
Oplustilova, Lenka ;
Aaltonen, Kirsimari ;
Tamminen, Anitta ;
Heikkinen, Tuomas ;
Mistrik, Martin ;
Aittomaki, Kristiina ;
Blomqvist, Carl ;
Heikkila, Paivi ;
Lukas, Jiri ;
Nevanlinna, Heli ;
Bartek, Jiri .
MOLECULAR ONCOLOGY, 2008, 2 (04) :296-316
[5]   Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts [J].
Bell, Daphne W. ;
Kim, Sang H. ;
Godwin, Andrew K. ;
Schiripo, Taryn A. ;
Harris, Patricia L. ;
Haserlat, Sara M. ;
Wahrer, Doke C. R. ;
Haiman, Christopher A. ;
Daly, Mary B. ;
Niendorf, Kristin B. ;
Smith, Matthew R. ;
Sgroi, Dennis C. ;
Garber, Judy E. ;
Olopade, Olufunmilayo I. ;
Le Marchand, Loic ;
Henderson, Brian E. ;
Altshuler, David ;
Haber, Daniel A. ;
Freedman, Matthew L. .
INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (12) :2661-2667
[6]   Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer [J].
Berwick, Marianne ;
Satagopan, Jaya M. ;
Ben-Porat, Leah ;
Carlson, Ann ;
Mah, Katherine ;
Henry, Rashida ;
Diotti, Raffaella ;
Milton, Kelly ;
Pujara, Kanan ;
Landers, Tom ;
Batish, Sat Dev ;
Morales, Jose ;
Schindler, Detlev ;
Hanenberg, Helmut ;
Hromas, Robert ;
Levran, Orna ;
Auerbach, Arleen D. .
CANCER RESEARCH, 2007, 67 (19) :9591-9596
[7]   ATM-heterozygous germline mutations contribute to breast cancer-susceptibility [J].
Broeks, A ;
Urbanus, JHM ;
Floore, AN ;
Dahler, EC ;
Klijn, JGM ;
Rutgers, EJT ;
Devilee, P ;
Russell, NS ;
van Leeuwen, FE ;
van't Veer, LJ .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 66 (02) :494-500
[8]   Functional assays for BRCA1 and BRCA2 [J].
Carvalho, Marcelo A. ;
Couch, Fergus J. ;
Monteiro, Alvaro N. A. .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2007, 39 (02) :298-310
[9]  
Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205
[10]   RAD51C Germline Mutations in Breast and Ovarian Cancer Cases from High-Risk Families [J].
Clague, Jessica ;
Wilhoite, Greg ;
Adamson, Aaron ;
Bailis, Adam ;
Weitzel, Jeffrey N. ;
Neuhausen, Susan L. .
PLOS ONE, 2011, 6 (09)